At a quick glance I found this, sure a bit lower but still borders on legal theft if you ask me, what other industry has such a mark up?https://www.theatlantic.com/health/a...hkreli/406546/
At a quick glance I found this, sure a bit lower but still borders on legal theft if you ask me, what other industry has such a mark up?https://www.theatlantic.com/health/a...hkreli/406546/
‘There is no God but Resister and Refugee is his messenger’.
Book of Democrat Things, Chapter 1:1
resister (08-05-2017)
Remember also that we protect the initial investment by giving people a 20 year exclusivity through patent protection. For drug companies, though, it really can be only 12 years b/c it can take 8 years to get FDA approval -- though I think they can extend it by 5 years to 14 years after FDA approval.
Any time you give a man something he doesn't earn, you cheapen him. Our kids earn what they get, and that includes respect. -- Woody Hayes
I'm not really sure but I think that some make them available earlier - or reverse engineer knockoffs?
Wait til Viagra (April 2020) and Cialis (End of 2017) expire. You'll see that price drop dramatically, I think. http://www.ipwatchdog.com/2017/04/12...ions/id=81619/
Any time you give a man something he doesn't earn, you cheapen him. Our kids earn what they get, and that includes respect. -- Woody Hayes
Bo-4 (08-05-2017)
Yeah, i do programs with major commercial truck manufacturers on sales and parts side.
Realizing that they had to compete with aftermarket knock-offs on parts, some of them have rebranded their stuff to compete in that particular space.
It's a pretty interesting game of cat and mouse!
I hope this idiot spends a lot of time behind bars.
I'm prancing like a pony.
Granny says, "Dat's right - kill alla lawyers...
Ex-lawyer for pharma exec Shkreli convicted of aiding fraud scheme
December 27, 2017 - A New York corporate lawyer who once advised Martin Shkreli was convicted on Wednesday of charges he helped the former pharmaceutical executive steal millions of dollars from a drug company to pay back investors in two failed hedge funds.
Evan Greebel, who was outside counsel to Shkreli’s former company Retrophin Inc (RTRX.O), was found guilty by a federal jury in Brooklyn of charges that he conspired to commit wire fraud and securities fraud, the U.S. government said. “We are shocked by the verdict,” said Reed Brodsky, a lawyer for Greebel. “We will continue to fight for justice for Evan Greebel and his family.” Greebel, 44, was a partner at the law firm Katten Muchin Rosenman when he was working for Retrophin. He later joined the firm Kaye Scholer, but resigned after his arrest in December 2015.
Shkreli, 34, became notorious in 2015 when he raised the price of anti-parasitic drug Daraprim to $750 a pill, from $13.50, as chief executive of Turing Pharmaceuticals. The price hike is not related to the criminal case. The charges he and Greebel faced related to Shkreli’s management of his previous drug company, Retrophin, and of two hedge funds, MSMB Capital and MSMB Healthcare, from 2009 to 2014.
A jury in August found Shkreli guilty of defrauding MSMB investors, but not guilty of conspiring with Greebel to steal from Retrophin. In September, following his conviction, Shkreli was jailed after he placed a $5,000 bounty on former presidential candidate Hillary Clinton’s hair, prompting U.S. District Judge Kiyo Matsumoto to revoke his bail. According to prosecutors, Greebel faces a maximum sentence of 20 years in prison on the wire fraud count.
https://in.reuters.com/article/usa-c...-idINKBN1EL1L3